CJC-1295 vs Growth Hormone
Head-to-head comparison of CJC-1295 and Growth Hormone for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Growth Hormone |
|---|---|---|
| Category | Growth Hormone Secretagogue | Hormone |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | Growth hormone binds to the GH receptor (GHR), a type I cytokine receptor, activating the JAK2-STAT5 signaling pathway. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved for multiple indications. First approved in 1985 (recombinant form). |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia); Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | Adults: 0.15–0.3 mg/day SC (GH deficiency); Pediatric: 0.025–0.05 mg/kg/day SC |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily (typically evening) |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~22,124 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~20-30 min (endogenous IV); SC injection effective duration ~12-16 hours |
Overview
CJC-1295 and Growth Hormone are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Growth Hormone — Mechanism & Evidence
Human growth hormone (hGH, somatotropin) is a 191-amino acid protein produced by the anterior pituitary gland. It is one of the most extensively studied hormones in medicine.
Key claims: Treats growth hormone deficiency in children; Treats adult growth hormone deficiency; Anti-aging effects.
Shared Research Applications
These peptides target different research areas. CJC-1295 focuses on Anti-Aging, Body Composition, while Growth Hormone targets GH Deficiency Treatment, Pediatric Growth Disorders, Reference.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Growth Hormone: Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia) Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes Fluid retention: peripheral edema, especially at treatment initiation
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
CJC-1295 vs Sermorelin: Comparing Growth Hormone-Releasing Peptides
Compare CJC-1295 vs Sermorelin for growth hormone release. Analyze mechanisms, preclinical data, and research limitations for these GHRH analogs.
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe